CareConekta: A Smartphone App to Improve Engagement in HIV Care

Not Applicable

Completed

Conditions: HIV/AIDS
Pregnancy Related

Interventions: Other: CareConekta

Registration Number: NCT03836625

Lead Sponsor: Vanderbilt University

Brief Summary: Population mobility is common in South Africa, but important research gaps exist describing this mobility and its impact on engagement in HIV care, particularly among pregnant and postpartum women. Through this study, the investigators propose to test a smartphone application - CareConekta - to conduct essential formative work on mobility and evaluate this app as an intervention to facilitate engagement in HIV care during times of mobility. This work is critical to adapting CareConekta for widespread use, providing critical information about mobility during the peripartum period and the impact on engagement in HIV care, and piloting this intervention to improve engagement.

Detailed Description: South Africa is home to the world's largest antiretroviral therapy (ART) program, but sustaining high retention along the HIV care continuum has proven challenging in the country and throughout the wider region. Population mobility is common in South Africa, but important research gaps exist describing this mobility and its impact on engagement in HIV care. Postpartum women and their infants in South Africa are known to be at high risk of dropping out of HIV care after delivery and are frequently mobile. The investigators recently developed a beta version of a smartphone application (app) - CareConekta - that detects a user's smartphone location to allow for prospective characterization of mobility. Through this three-year study, the investigators propose to test CareConekta to conduct essential formative work on mobility and evaluate an intervention - the CareConekta app plus text notifications and optional staff phone calls and/or WhatsApp messages - to facilitate engagement in HIV care during times of mobility. After first adapting CareConekta to use appropriate smartphone technology for the local population, the investigators will characterize mobility among South African women during the peripartum period and its impact on engagement in HIV care. The investigators also will evaluate the acceptability, feasibility, and initial efficacy of using CareConekta as an intervention to improve engagement in HIV care. The investigators will work with a South African technology company with a strong connection to the South African Department of Health to adapt the app prior to enrolling study participants. The study will observe mobility within an observational cohort and will then assess the impact of the intervention among participants who travel during the study period. This work is critical to adapting an existing app for widespread use, providing critical information about mobility during the peripartum period and the impact on engagement in HIV care, and piloting an intervention to improve engagement. This study will lay the necessary groundwork for a larger efficacy trial of the intervention within different geographic settings.

Recruitment & Eligibility

Status: COMPLETED

Sex: Female

Target Recruitment: 200

Inclusion Criteria

We will only enroll participants attending the Gugulethu Community Health Centre, near Cape Town, South Africa
HIV-positive
adult (≥18 years)
pregnant (≥28 weeks)
own a smartphone that meets the technical requirements
willing to opt-in to installation of CareConekta on her personal phone and to mobility tracking
demonstrate the ability to read simple text language
willing to be randomized

Exclusion Criteria

If an interested participant meets all of the inclusion criteria, there are no additional exclusion criteria

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Intervention	CareConekta	The intervention arm will receive standard CareConekta, plus text notifications of nearby ART facilities when they have traveled \>50 km from the study site for \>7 days. At enrollment, participants in the intervention arm also will be able to opt-in to phone call(s) and/or WhatsApp message(s) from study staff to when they have met this travel threshold. The study staff calls and messages will ask about medication supply and will provide assistance with nearby facilities, if requested.

Primary Outcome Measures

Name	Time	Method
Mobility Prevalence	Baseline to End of Study (up to 2 years)	The investigators will report the number of participants who travel during the study period (defined as 3 or more nights away from home), over the denominator of all participants who completed follow-up.
Median Number of Trips Per Person	Baseline to End of Study (up to 2 years)	Among those who travel, the investigators will report the median and interquartile range number of trips during the study period.
CareConekta Feasibility: Same Phone at Follow-up	Baseline to End of Study (up to 2 years)	The number of participants who report using the same phone from enrollment at follow-up

Secondary Outcome Measures

Name	Time	Method
Permanent Move	Baseline to End of Study (up to 2 years)	Was the move permanent (yes/no)
CareConekta Feasibility: GPS Disabled During the Study Period	Baseline to End of Study (up to 2 years)	The number of participants who disabled GPS during the study period
Impact of Mobility -- Maternal Engagement in HIV Care	6 months after delivery	In the standard arm, the investigators will assess the association (estimating hazard ratios) between mobility during the study period and engagement in HIV care for the mother (defined as retention in care and viral suppression six months after delivery).
CareConekta Feasibility -- Participant Reported Sharing Phone	Baseline to End of Study (up to 2 years)	The number of participants who reported sharing their phone with another person during the study period
CareConekta Initial Efficacy -- Infant Outcomes	10 weeks after delivery, study end	The investigators will assess the initial efficacy of CareConekta as an intervention to improve engagement in HIV care. Efficacy will be assessed as the association (estimating adjusted hazard ratios) between study arm and vertical HIV transmission and completion of 10-week infant HIV PCR test.
Timing of Travel	Baseline to End of Study (up to 2 years)	The investigators will determine timing of travel as it relates to delivery date, which will be obtained from participant questionnaire.
CareConekta Feasibility -- Participant Ever Opened App	Baseline to End of Study (up to 2 years)	The number of participants who reported opening the CareConekta app at least once after enrollment visit
CareConekta Feasibility -- Participant Used the App to Locate New Health Facilities	Baseline to End of Study (up to 2 years)	The number of participants who reported using the CareConekta app to locate a new health facility.
CareConekta Initial Efficacy -- Maternal Engagement in HIV Care	6 months after delivery	The investigators will assess the initial efficacy of CareConekta as an intervention to improve engagement in HIV care. Efficacy will be assessed as the association (estimating adjusted hazard ratios) between study arm and maternal retention in care and viral suppression 6 months after delivery.
Impact of Mobility -- Infant Outcomes	10 weeks after delivery, study end	In the standard arm, the investigators will assess the association (estimating hazard ratios) between mobility during the study period and completion of routine early infant diagnosis.